Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • maxcoatinc maxcoatinc Jun 4, 2012 10:27 AM Flag

    Awfully quit here...

    Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
    Date/Time: Monday, June 4, 2012; 10:15 AM — 10:30 AM (CT)
    Location: E354a
    Abstract # 6507: The Bruton's tyrosine kinase inhibitor PCI-32765 in treatment-naive chronic lymphocytic leukemia patients: Interim results of a phase Ib/II study. Dr. John C. Byrd et al., The Ohio State University, Columbus, Ohio.
    This Abstract was selected to be presented at the "Best of ASCO Meetings."

    Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
    Date/Time: Monday, June 4, 2012; 10:30 AM — 10:45 AM (CT)
    Location: E354a
    Abstract # 6508: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. Dr. Samantha Mary Jaglowski et al. The Ohio State University, Columbus, Ohio.

    Poster Discussion Session at ASCO, Chicago, IL (June 1-5, 2012)
    Date/Time: Friday, June 1, 2012; 4:30 PM — 5:30 PM (CT)
    Location: S405
    Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study. Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
PCYC
257.100.00(0.00%)Apr 23 3:59 PMEDT